EGRX - Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma

Eagle Pharmaceuticals (EGRX) announces that Treakisym ready-to-dilute ((RTD)) (bendamustine hydrochloride 120 mg/m2) liquid formulation has been approved for a new indication in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL”) by the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan. “Based on this additional indication, as well as the anticipated approval of the ten-minute RI liquid formulation, we are reiterating our belief that the combined royalty and milestones revenue from these products will generate $25 million at peak,” stated Scott Tarriff, CEO. In September 2017, Eagle licensed to SymBio intellectual property necessary to develop, market and sell RTD and RI formulations of bendamustine under the trade name Treakisym in Japan utilizing Eagle’s technology.SymBio received approval for the Treakisym RTD (250 ml) liquid formulation in September 2020 and is currently conducting a clinical safety trial for the ten-minute RI (50 ml) liquid formulation, for which

For further details see:

Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma